Accelus announced the successful completion of the first surgery integrating its Remi™ Robotic Navigation, LineSider® Spinal System and FlareHawk® Expandable Interbody Fusion Device systems in one procedure.
The Remi platform provides robotic-assisted placement of the LineSider Spinal System, a low-profile, minimally invasive pedicle screw system utilizing extended tab technology. FlareHawk, Accelus’ flagship product, features proprietary multidirectional expansion technology, designed to minimize neural retraction during implant insertion.
“Since our inception, Accelus has been focused on designing products that reconcile the desire of spine surgeons for a minimally invasive approach with the need for maximum clinical results,” said Chris Walsh, CEO and Co-Founder of Accelus. “Successful outcomes from procedures validate our mission, and we look forward to expanding our scope to a variety of surgical approaches that can be performed across several clinical settings, including ASCs, in the future.”
Accelus announced the successful completion of the first surgery integrating its Remi™ Robotic Navigation, LineSider® Spinal System and FlareHawk® Expandable Interbody Fusion Device systems in one procedure.
The Remi platform provides robotic-assisted placement of the LineSider Spinal System, a low-profile, minimally invasive pedicle screw...
Accelus announced the successful completion of the first surgery integrating its Remi™ Robotic Navigation, LineSider® Spinal System and FlareHawk® Expandable Interbody Fusion Device systems in one procedure.
The Remi platform provides robotic-assisted placement of the LineSider Spinal System, a low-profile, minimally invasive pedicle screw system utilizing extended tab technology. FlareHawk, Accelus’ flagship product, features proprietary multidirectional expansion technology, designed to minimize neural retraction during implant insertion.
“Since our inception, Accelus has been focused on designing products that reconcile the desire of spine surgeons for a minimally invasive approach with the need for maximum clinical results,” said Chris Walsh, CEO and Co-Founder of Accelus. “Successful outcomes from procedures validate our mission, and we look forward to expanding our scope to a variety of surgical approaches that can be performed across several clinical settings, including ASCs, in the future.”
Copy to clipboard 
